Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own0.60% Shs Outstand41.44M Perf Week3.23%
Market Cap2.25B Forward P/E- EPS next Y-4.58 Insider Trans-94.42% Shs Float33.51M Perf Month25.78%
Income-67.70M PEG- EPS next Q-0.72 Inst Own92.10% Short Float8.02% Perf Quarter5.54%
Sales33.60M P/S66.98 EPS this Y-1.60% Inst Trans2.80% Short Ratio4.77 Perf Half Y-11.91%
Book/sh9.21 P/B5.90 EPS next Y-30.10% ROA-17.70% Target Price77.56 Perf Year4.04%
Cash/sh7.59 P/C7.15 EPS next 5Y- ROE-20.00% 52W Range39.01 - 67.79 Perf YTD11.15%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-19.90% 52W High-19.88% Beta2.48
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low39.22% ATR2.46
Employees165 Current Ratio8.70 Sales Q/Q313.30% Oper. Margin- RSI (14)64.33 Volatility3.73% 5.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-37.30% Profit Margin- Rel Volume1.41 Prev Close55.82
ShortableYes LT Debt/Eq0.00 EarningsMar 14 Payout- Avg Volume562.80K Price54.31
Recom1.60 SMA208.04% SMA5018.79% SMA2002.59% Volume793,203 Change-2.71%
Oct-01-18Initiated Cantor Fitzgerald Overweight $90
Sep-28-18Initiated Citigroup Buy $90
Sep-10-18Initiated Morgan Stanley Overweight $72
Jul-10-18Initiated BofA/Merrill Buy $71
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Mar-06-19 08:00AM  MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference GlobeNewswire
Mar-05-19 10:02PM  Edited Transcript of MYOK earnings conference call or presentation 4-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
08:48AM  MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher Zacks
Mar-04-19 09:42AM  MyoKardia stock up 6% after safety-and-efficacy study of HCM treatment shows reduction in symptoms MarketWatch +7.27%
08:02AM  MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM GlobeNewswire
Feb-28-19 09:28AM  Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million American City Business Journals
08:30AM  MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-26-19 05:28PM  Big Pharma trims projects and a potential $1 billion in payments from collaboration with small Peninsula biotech American City Business Journals
Feb-21-19 04:00PM  3 Top Healthcare Stocks to Buy in February Motley Fool
Feb-11-19 10:42AM  Zacks.com featured highlights include: Athene, MyoKardia and Euronav Zacks
Feb-08-19 08:55AM  3 Earnings Acceleration Stocks You Really Need to Look At Zacks
Feb-04-19 01:58PM  MyoKardia, Inc. (NASDAQ:MYOK) Insiders Have Been Selling Simply Wall St.
08:15AM  Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-23-19 08:30AM  MyoKardia Appoints William Fairey as Chief Commercial Officer GlobeNewswire
Jan-13-19 11:14AM  Weekly CEO Buys Highlight GuruFocus.com
Jan-09-19 04:05PM  Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019 TheStreet.com
Jan-03-19 08:00AM  MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-19 04:35PM  Why Tesla, MyoKardia, and Hologic Slumped Today Motley Fool -14.14%
08:00AM  MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi GlobeNewswire
Dec-14-18 01:42AM  Hedge Funds Are Buying MyoKardia, Inc. (MYOK) Insider Monkey
Dec-11-18 08:30AM  MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients GlobeNewswire
Dec-05-18 04:01PM  MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-18 08:38AM  Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Nov-28-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy Fundamental Analysis, Key Performance Indications GlobeNewswire +6.18%
Nov-12-18 07:30AM  MyoKardia Presents Preclinical Evidence of Mavacamtens Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-08-18 05:34PM  Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals +6.99%
Nov-07-18 08:50PM  MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:48PM  MyoKardia: 3Q Earnings Snapshot Associated Press
04:38PM  All this 500,000-square-foot Berkeley biotech project needs is a developer American City Business Journals
04:30PM  MyoKardia Reports Third Quarter 2018 Financial Results GlobeNewswire
08:01AM  MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 08:00AM  MyoKardia to Present Clinical Evidence of Mavacamtens Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions GlobeNewswire
08:00AM  MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-01-18 10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals
Oct-31-18 10:10AM  Bears Are Doing an EKG Test on MyoKardia TheStreet.com
Oct-30-18 07:30AM  MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day GlobeNewswire
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals -5.69%
Oct-25-18 10:34AM  MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up? Zacks +6.00%
12:00AM  MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe GlobeNewswire
Oct-24-18 04:30PM  MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy GlobeNewswire -6.60%
Oct-22-18 08:30AM  MyoKardia to Host R&D Day on October 30, 2018 GlobeNewswire
Oct-19-18 08:30AM  Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
08:01AM  MyoKardia to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
Aug-29-18 04:01PM  MyoKardia to Present at Two Upcoming Investor Conferences in September GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-08-18 08:05PM  MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:02PM  MyoKardia: 2Q Earnings Snapshot Associated Press
04:02PM  MyoKardia Reports Second Quarter 2018 Financial Results GlobeNewswire
03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals
02:30PM  MyoKardia, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 04:01PM  MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference GlobeNewswire
Aug-01-18 04:30PM  MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018 GlobeNewswire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE +5.17%
Jul-10-18 02:06PM  BofA Revives Myokardia With New Buy Rating Benzinga
Jul-03-18 08:10AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and MyoKardia ACCESSWIRE
Jun-26-18 08:30AM  MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
Jun-06-18 08:30AM  Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-22-18 08:05PM  MyoKardia Announces Pricing of Public Offering of Common Stock GlobeNewswire
May-21-18 04:01PM  MyoKardia Announces Proposed Public Offering of Common Stock GlobeNewswire -6.57%
07:30AM  MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
May-18-18 07:07PM  Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55? Simply Wall St.
May-17-18 01:39PM  Inspire Awards 2018: Mary Cranston on why women need to push back on stereotypes about leadership American City Business Journals
May-10-18 04:30PM  MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
08:30AM  MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
May-09-18 02:35PM  Edited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents -7.42%
May-08-18 05:44PM  MyoKardia: 1Q Earnings Snapshot Associated Press
04:01PM  MyoKardia Reports First Quarter 2018 Financial Results GlobeNewswire
May-03-18 04:01PM  MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018 GlobeNewswire
Apr-09-18 08:10AM  New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-04-18 08:30AM  MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer GlobeNewswire
Apr-02-18 08:30AM  MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
Mar-16-18 08:15AM  Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-09-18 09:50AM  Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 05:28PM  MyoKardia reports 4Q loss Associated Press
04:03PM  MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
04:02PM  MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
01:15PM  MyoKardia, Inc. to Host Earnings Call ACCESSWIRE
09:34AM  Earnings Preview For MyoKardia Benzinga
Mar-06-18 08:00AM  MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 04:30PM  MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018 GlobeNewswire
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Endocyte and MyoKardia ACCESSWIRE -5.56%
Feb-14-18 04:30PM  MyoKardia to Present at the RBC Capital Markets 2018 Healthcare Conference GlobeNewswire +6.53%
08:30AM  MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients GlobeNewswire
Jan-19-18 08:30AM  MyoKardia Announces Appointment of Cynthia Ladd as General Counsel GlobeNewswire
Jan-16-18 03:50PM  Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Jan-10-18 12:08PM  4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE) SmarterAnalyst
Jan-03-18 04:30PM  MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-17 11:51AM  ETFs with exposure to MyoKardia, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:21AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-11-17 07:25AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017 Capital Cube
Nov-15-17 08:00AM  Preclinical Studies with MyoKardias Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance GlobeNewswire
Nov-13-17 07:15PM  MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor GlobeNewswire
Nov-08-17 09:44AM  MyoKardia, Inc. Value Analysis (NASDAQ:MYOK) : November 8, 2017 Capital Cube
Nov-07-17 12:48PM  Myokardia Inc (MYOK) Q3:17 Update At First Glance SmarterAnalyst
Nov-06-17 07:17AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017 Capital Cube
Nov-02-17 05:54PM  MyoKardia reports 3Q loss Associated Press
04:02PM  MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress GlobeNewswire
Nov-01-17 08:00AM  MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions GlobeNewswire
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee JuneSee RemarksMar 14Option Exercise11.951,75821,0084,178Mar 18 05:32 PM
Sanofi10% OwnerFeb 13Sale37.664,168,899157,000,7360Feb 15 06:05 AM
GIANAKAKOS ANASTASIOSPresident and CEOJan 07Sale44.112,770122,19776,967Jan 11 08:18 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 04Buy39.862,50099,64788,473Jan 08 07:12 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 12Sale55.683,000167,04572,087Dec 13 08:41 PM
Lee JuneSee RemarksDec 03Option Exercise11.955,00059,7505,770Dec 06 08:13 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 05Option Exercise1.513,0004,52078,087Nov 06 07:32 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 05Sale56.573,000169,71675,087Nov 06 07:32 PM
Bauer JakeChief Business OfficerNov 02Sale55.4597854,23059,900Nov 06 07:30 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Option Exercise1.513,0004,52077,949Oct 05 09:13 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Sale58.193,000174,57874,949Oct 05 09:13 PM
Lee JuneSee RemarksSep 21Option Exercise11.955,00059,7505,426Sep 24 08:26 PM
Lee JuneSee RemarksSep 21Sale63.135,000315,652426Sep 24 08:26 PM
Semigran MarcChief Medical OfficerSep 05Option Exercise15.953,60057,4203,600Sep 06 05:00 PM
Semigran MarcChief Medical OfficerSep 05Sale60.003,600216,0000Sep 06 05:00 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 04Option Exercise1.513,0004,52077,949Sep 06 04:59 PM
Semigran MarcChief Medical OfficerSep 04Option Exercise15.9541,400660,33041,400Sep 06 05:00 PM
Semigran MarcChief Medical OfficerSep 04Sale59.4941,4002,463,0060Sep 06 05:00 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 04Sale59.333,000178,00474,949Sep 06 04:59 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 06Option Exercise1.513,0004,52077,949Aug 08 06:54 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 06Sale57.473,000172,41074,949Aug 08 06:54 PM
Bauer JakeChief Business OfficerJul 23Option Exercise13.907,500104,25068,106Jul 25 04:17 PM
Bauer JakeChief Business OfficerJul 23Sale56.887,500426,56560,606Jul 25 04:17 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 05Option Exercise1.513,0004,52077,949Jul 06 06:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 05Sale53.133,000159,37974,949Jul 06 06:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 04Option Exercise1.513,0004,52077,949Jun 06 07:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 04Sale46.953,000140,86474,949Jun 06 07:34 PM
Sanofi10% OwnerMay 25Buy49.00150,0007,350,0004,168,899May 29 04:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Option Exercise1.512,9814,49277,949May 07 09:47 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Sale47.573,000142,70074,949May 07 09:47 PM
Bauer JakeChief Business OfficerMay 03Sale48.951,51974,35560,606May 07 05:43 PM
Bauer JakeSee RemarksApr 11Option Exercise12.255,00061,25066,777Apr 12 08:32 PM
Bauer JakeSee RemarksApr 11Sale50.005,000250,00061,777Apr 12 08:32 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Option Exercise1.513,0004,52077,390Apr 05 07:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Sale47.953,000143,86374,390Apr 05 07:48 PM
Bauer JakeSee RemarksMar 26Option Exercise9.081641,48961,941Mar 28 04:08 PM
Bauer JakeSee RemarksMar 26Sale50.951648,35661,777Mar 28 04:08 PM